Form 4: Rockwell Medical CEO Sells Shares Under Pre-Arranged Trading Plan

Rockwell Medical, Inc.'s President and CEO, Mark Strobeck, sold 6,926 shares of common stock at a weighted average price of $0.82 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Mark Strobeck, who serves as President and CEO and a Director of Rockwell Medical, Inc. (RMTI), disposed of 6,926 shares of the company's common stock.
• The transaction occurred on July 1, 2025, with the shares sold at a weighted average price of $0.82 per share, with individual trades ranging from $0.81 to $0.84.
• This sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which Mr. Strobeck adopted on May 30, 2024.
• Following this reported transaction, Mr. Strobeck beneficially owns 337,752 shares of Rockwell Medical common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be perceived negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 plan mitigates concerns that it is based on new, adverse non-public information. Such sales are often for personal financial planning.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a discretionary sale based on new, non-public information.

Negatives

• Mark Strobeck, President and CEO, sold 6,926 shares of common stock, which could be perceived as a negative signal by some investors.

Future Outlook

No forward-looking statements or guidance were provided in this document.

Management Comments

• The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

This document details an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale by a key executive could be perceived negatively, potentially signaling a lack of confidence, although the Rule 10b5-1 plan mitigates this concern by indicating a pre-scheduled transaction.

Key Dates

Recommendation

Keywords

Rockwell Medical, RMTI, Mark Strobeck, Insider Trading, Form 4, Stock Sale, CEO, Director, Rule 10b5-1, Common Stock